

PTO/SB/084 (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays	a valid OMB control number.
Confirmation Number	3740
Application Number	10/690,115
Filing Date	10/21/2003
First Named Inventor	Richard Apodaca
Group Art Unit	1624
Examiner Name	Brenda L. Coleman
Attorney Docket Number	PRD2033USNP

	Cite	U.S. Patent Document					
Examiner Initials		Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document		umns, Lines, nt passages or ures appear
BC		5,464,788	Ą	Bock et al.	11-07-1995	514	253.
BC	_	5,569,659	Α	Reitz	10-29-1996	514	253.1
BC	r	5,681,954	Α	Yamamoto et al.	10-28-1997	544	- 114
deepl	تمما	<del>5</del> ,883,096	A-	Lowe et al.	03-16-1999	514	-+7
BC		5,900,422	. A	Ali	05-04-1999	514	316
		•			·		
							•

lakinh		Foreign Patent Document		ent	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
	Cite No. <sup>1</sup>	Office <sup>3</sup> KindCo	Number <sup>4</sup> de <sup>5</sup>		Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	14.
BC		EP	06245 84	B1	Daiichi Pharmceutical Co., Ltd.	08-19-1998	see US Patent 5,681,954	
BC		JP	Hei 10- 59954		Takeda Pharmaceutical Co., Ltd.	03-03-1998		х
BC		wo	93/046 84	A1	McNeilab, Inc.	03-18-1993	see p. 40, Table 4, compound 11	
BC		wo	05/035 534	A1	Ono Pharmaceutical Co., LTD	04-21-2005	see English- translated claims	x

FOREIGN PATENT DOCUMENTS

Examiner Brende Coleman Date Considered May 25, 2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sertal number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

\*\* structures only.

\*\*

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

Confirmation Number	3740
Application Number	10/690,115
Filing Date	10/21/2003
First Named Inventor	Richard Apodaca
Group Art Unit	1624
Examiner Name	Branda L. Coleman
Attorney Docket Number	PRD2033USNP

ſ			OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
	Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	BC		AICHER, T.D. et al.: "Secondary Amides of (R) -3,3,3-Trifluoro-2-hydroxy-2-methylpropionic Acid as Inhibitors of Pyruvate Dehydrogenase Kinase"; J. Med. Chem. 2000, 43, 236-249.	
×	BC)		AUGUSTIN, M. et al.: Zeitschrift fuer Chemie 1967, 7(10), 389.	
	BC		HIRT, R. et al.: Experientia 1961, 17, 418-20.	
*	Be		NAKAMURA, M. et al.: "The Preparation of Oligo(ethylenepiperazine)'s and the Polyamine-polyamides Thereof"; Kenkyu Hokoku - Asahi Garasu Kogyo Gijutsu Shoreikai 1973, 23, 297-308.	
•				
ŀ				
L				

Examiner Signature	Brenda	Coleman	Date Considered	May	25	2007

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\*\* structures only

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

## SUBMISSION UNDER MPEP 609.06

Page 1 of 1

Application Number	10/690115
Confirmation Number	3740
Filing Date	10/21/2003
First Named Inventor	Richard Apodaca
Group Art Unit	1624
Examiner Name	Brenda L. Coleman
Attorney Docket Number	PRD2033USNP

		IIS DA	TENT DOCUMENTS		TREECOCON	
		U.S. FA	U.S. Patent Document			
Examiner Initials	Cite No. <sup>1</sup>	Name of Patentee or Applicant of Cited Document	Kind Code <sup>2</sup> Number (if known)		Pages, Columns, Lines, where relevant passages of relevant figures appear	
BC		Allison et al.	11/531,849			
				-		
·						

Examiner I			Date			
0:	Drende	/ ./	Den	(Y)	75	2007
Signature	/ Donas	Coceman	Considered	i vay	みつ、	900 J